Follicle-stimulating hormone promotes RANK expression on human monocytes

Joseph Gerard Cannon, Barbara J Kraj, Gloria Sloan

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Elevated serum concentrations of follicle-stimulating hormone (FSH) are associated with diminished bone density in women, beginning years before menopause and the decline in estradiol. We hypothesized that FSH promotes development of myeloid cells toward the bone-resorbing osteoclast phenotype. This was tested by isolating peripheral blood mononuclear cells from nine healthy adults, incubating them in the presence of FSH at three different concentrations spanning the physiological range, and then measuring the expression of receptor activator for NF-κB (RANK, a surface marker for osteoclasts) on CD14+ cells by flow cytometry. In the absence of FSH, 3.3±0.5% of the cells expressed high levels of the receptor (RANKhigh). Increasing concentrations of FSH caused a biphasic dose-response, with a maximal (1.5-fold) increase in RANKhigh cells achieved with 50mIU/ml FSH (P=0.02). Cytokines that influence development of osteoclasts were also measured in culture supernatants: macrophage colony stimulating factor (M-CSF), osteoprotegerin (OPG) and tumor necrosis factor-α (TNFα) concentrations were not significantly influenced by FSH, whereas RANK-ligand was undetectable. This study supports the concept that the elevated circulating concentrations of FSH during perimenopause may contribute to the increased rate of bone loss by promoting the development of osteoclast precursor cells.

Original languageEnglish (US)
Pages (from-to)141-144
Number of pages4
JournalCytokine
Volume53
Issue number2
DOIs
StatePublished - Feb 1 2011

Fingerprint

Follicle Stimulating Hormone
Monocytes
Osteoclasts
Bone
Perimenopause
RANK Ligand
Osteoprotegerin
Bone and Bones
Macrophage Colony-Stimulating Factor
Flow cytometry
Myeloid Cells
Menopause
Bone Density
Estradiol
Blood Cells
Flow Cytometry
Blood
Tumor Necrosis Factor-alpha
Cytokines
Phenotype

Keywords

  • Flow cytometry
  • Follicle-stimulating hormone
  • Human
  • Monocytes
  • RANK

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Hematology
  • Biochemistry
  • Molecular Biology

Cite this

Follicle-stimulating hormone promotes RANK expression on human monocytes. / Cannon, Joseph Gerard; Kraj, Barbara J; Sloan, Gloria.

In: Cytokine, Vol. 53, No. 2, 01.02.2011, p. 141-144.

Research output: Contribution to journalArticle

Cannon, Joseph Gerard ; Kraj, Barbara J ; Sloan, Gloria. / Follicle-stimulating hormone promotes RANK expression on human monocytes. In: Cytokine. 2011 ; Vol. 53, No. 2. pp. 141-144.
@article{ebcbfa25e2404b3fa8af878506a36f1f,
title = "Follicle-stimulating hormone promotes RANK expression on human monocytes",
abstract = "Elevated serum concentrations of follicle-stimulating hormone (FSH) are associated with diminished bone density in women, beginning years before menopause and the decline in estradiol. We hypothesized that FSH promotes development of myeloid cells toward the bone-resorbing osteoclast phenotype. This was tested by isolating peripheral blood mononuclear cells from nine healthy adults, incubating them in the presence of FSH at three different concentrations spanning the physiological range, and then measuring the expression of receptor activator for NF-κB (RANK, a surface marker for osteoclasts) on CD14+ cells by flow cytometry. In the absence of FSH, 3.3±0.5{\%} of the cells expressed high levels of the receptor (RANKhigh). Increasing concentrations of FSH caused a biphasic dose-response, with a maximal (1.5-fold) increase in RANKhigh cells achieved with 50mIU/ml FSH (P=0.02). Cytokines that influence development of osteoclasts were also measured in culture supernatants: macrophage colony stimulating factor (M-CSF), osteoprotegerin (OPG) and tumor necrosis factor-α (TNFα) concentrations were not significantly influenced by FSH, whereas RANK-ligand was undetectable. This study supports the concept that the elevated circulating concentrations of FSH during perimenopause may contribute to the increased rate of bone loss by promoting the development of osteoclast precursor cells.",
keywords = "Flow cytometry, Follicle-stimulating hormone, Human, Monocytes, RANK",
author = "Cannon, {Joseph Gerard} and Kraj, {Barbara J} and Gloria Sloan",
year = "2011",
month = "2",
day = "1",
doi = "10.1016/j.cyto.2010.11.011",
language = "English (US)",
volume = "53",
pages = "141--144",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Follicle-stimulating hormone promotes RANK expression on human monocytes

AU - Cannon, Joseph Gerard

AU - Kraj, Barbara J

AU - Sloan, Gloria

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Elevated serum concentrations of follicle-stimulating hormone (FSH) are associated with diminished bone density in women, beginning years before menopause and the decline in estradiol. We hypothesized that FSH promotes development of myeloid cells toward the bone-resorbing osteoclast phenotype. This was tested by isolating peripheral blood mononuclear cells from nine healthy adults, incubating them in the presence of FSH at three different concentrations spanning the physiological range, and then measuring the expression of receptor activator for NF-κB (RANK, a surface marker for osteoclasts) on CD14+ cells by flow cytometry. In the absence of FSH, 3.3±0.5% of the cells expressed high levels of the receptor (RANKhigh). Increasing concentrations of FSH caused a biphasic dose-response, with a maximal (1.5-fold) increase in RANKhigh cells achieved with 50mIU/ml FSH (P=0.02). Cytokines that influence development of osteoclasts were also measured in culture supernatants: macrophage colony stimulating factor (M-CSF), osteoprotegerin (OPG) and tumor necrosis factor-α (TNFα) concentrations were not significantly influenced by FSH, whereas RANK-ligand was undetectable. This study supports the concept that the elevated circulating concentrations of FSH during perimenopause may contribute to the increased rate of bone loss by promoting the development of osteoclast precursor cells.

AB - Elevated serum concentrations of follicle-stimulating hormone (FSH) are associated with diminished bone density in women, beginning years before menopause and the decline in estradiol. We hypothesized that FSH promotes development of myeloid cells toward the bone-resorbing osteoclast phenotype. This was tested by isolating peripheral blood mononuclear cells from nine healthy adults, incubating them in the presence of FSH at three different concentrations spanning the physiological range, and then measuring the expression of receptor activator for NF-κB (RANK, a surface marker for osteoclasts) on CD14+ cells by flow cytometry. In the absence of FSH, 3.3±0.5% of the cells expressed high levels of the receptor (RANKhigh). Increasing concentrations of FSH caused a biphasic dose-response, with a maximal (1.5-fold) increase in RANKhigh cells achieved with 50mIU/ml FSH (P=0.02). Cytokines that influence development of osteoclasts were also measured in culture supernatants: macrophage colony stimulating factor (M-CSF), osteoprotegerin (OPG) and tumor necrosis factor-α (TNFα) concentrations were not significantly influenced by FSH, whereas RANK-ligand was undetectable. This study supports the concept that the elevated circulating concentrations of FSH during perimenopause may contribute to the increased rate of bone loss by promoting the development of osteoclast precursor cells.

KW - Flow cytometry

KW - Follicle-stimulating hormone

KW - Human

KW - Monocytes

KW - RANK

UR - http://www.scopus.com/inward/record.url?scp=78651078968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651078968&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2010.11.011

DO - 10.1016/j.cyto.2010.11.011

M3 - Article

VL - 53

SP - 141

EP - 144

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 2

ER -